This may be useful in tailoring therapy to a specific tumour phenotype in as much as SP-G may be more beneficial in V1A receptor expressing tumours while SP-D may be better for tumours, which express both GRP and V1A receptors. The gene discussed is GRP; the disease is neoplasm.